Drugs / Axi-cel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06213311 | May 2024 → Jul 2027 expected | large B-cell lymphoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT05370547 Background | May 2022 → Jun 2024 | non-Hodgkin lymphoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05641428 Comparator | Oct 2022 → Dec 2025 overdue | diffuse large B-cell lymphoma | University Medical Center Groningen | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Axi-cel | “A single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 100 × 10\^6 for Relma-cel or 2 × 10\^6/kg for Axi-cel.” NCT05370547 ↗ |
| Modality | Cell therapy | “CAR-transduced autologous T cells” NCT05370547 ↗ |
| Route | Intravenous | “CAR-transduced autologous T cells administered intravenously” NCT05370547 ↗ |